OCGN
NASDAQ · Biotechnology
Ocugen Inc
$0.93
+0.11 (+13.29%)
Open$0.83
Previous Close$0.82
Day High$0.97
Day Low$0.83
52W High$2.73
52W Low$0.69
Volume—
Avg Volume6.97M
Market Cap317.14M
P/E Ratio—
EPS$-0.20
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+3,140.0% upside
Current
$0.93
$0.93
Target
$29.97
$29.97
$22.68
$29.97 avg
$39.58
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 5.33M | 214.85M | 205.76M |
| Net Income | -81,958,544 | -16,849,465 | -19,542,916 |
| Profit Margin | -1,537.4% | -7.8% | -9.5% |
| EBITDA | -73,109,923 | -26,350,714 | -23,624,019 |
| Free Cash Flow | — | -15,177,197 | -13,829,123 |
| Rev Growth | — | +3.8% | +8.3% |
| Debt/Equity | 0.97 | 0.42 | 0.45 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $291.31 | +1.07% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $460.42 | +0.03% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $166.89 | -0.41% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $547.09 | +0.85% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $904.35 | +0.16% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $155.94 | -0.46% | 7.7 | 20.98B |